Core Viewpoint - A class action lawsuit has been filed against DoubleVerify Holdings, Inc. for alleged securities fraud and unlawful business practices [2][3]. Company Performance - On February 28, 2024, DoubleVerify lowered its revenue growth expectations for Q1 2024, leading to a stock price drop of $8.35, or 21.3%, closing at $30.89 on February 29, 2024 [3]. - On May 7, 2024, the company cut its full-year 2024 revenue outlook due to reduced ad spending from customers, resulting in a stock price decline of $11.79, or 38.6%, closing at $18.78 on May 8, 2024 [4]. - On February 27, 2025, DoubleVerify reported lower-than-expected Q4 2024 sales and earnings, attributed to reduced customer spending and a shift in ad dollars, causing a stock price drop of approximately 36% to close at $13.90 on February 28, 2025 [5]. Industry Concerns - On March 28, 2025, Adalytics Research, LLC released a report claiming that DoubleVerify's advertisement verification services are ineffective, stating that customers are billed for ad impressions served to bots [6]. - The Wall Street Journal reported that DoubleVerify frequently fails to detect nonhuman traffic, contradicting the company's claims of helping brands avoid serving ads to bot accounts [6].

Core Viewpoint - NeuroPace, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing results from a clinical study [1][3]. Group 1: Company Performance - On May 27, 2025, NeuroPace announced the preliminary one-year results of the NAUTILUS study, which evaluated the safety and effectiveness of the RNS System for treating drug-resistant idiopathic generalized epilepsy (IGE) [3]. - The study did not achieve statistical significance for its primary effectiveness endpoint, which aimed to demonstrate a longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation group [3]. - Following the announcement, NeuroPace's stock price dropped by $5.02 per share, or 28.39%, closing at $12.66 per share on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of NeuroPace investors regarding possible securities fraud or other unlawful business practices by the company and its officers and/or directors [1]. - Investors are encouraged to contact Pomerantz LLP for more information about the investigation and potential class action [1].

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Semler Scientific Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Disclosure - On February 28, 2025, Semler filed its annual report for 2024, indicating a risk of a complaint from the U.S. Department of Justice (DOJ) related to a civil False Claims Act lawsuit [3]. - Semler disclosed receiving an initial civil investigative demand from the DOJ in July 2017 concerning reimbursement claims for its QuantaFlo device [3]. - The company participated in unsuccessful settlement discussions with the DOJ in February 2025 [3]. Group 2: Market Reaction - Following the news of the DOJ investigation, Semler's stock price dropped by $4.03 per share, or 9.4%, closing at $38.89 per share on March 3, 2025 [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Savara Inc. following a significant stock price drop after the FDA's refusal to file letter regarding its drug application [1][3]. Company Summary - Savara Inc. received a refusal to file letter from the FDA for its Biologics License Application for MOLBREEVI, intended to treat autoimmune PAP [3]. - Following this announcement, Savara's stock price decreased by $0.90, representing a 31.69% decline, closing at $1.94 per share on May 27, 2025 [3]. Legal Investigation - Pomerantz LLP is representing investors of Savara and is looking into claims of securities fraud or other unlawful practices by the company and its officers or directors [1].

Core Viewpoint - A class action lawsuit has been filed against DoubleVerify Holdings, Inc. for alleged securities fraud and unlawful business practices, with investors encouraged to join the lawsuit [1][2]. Company Performance - On February 28, 2024, DoubleVerify lowered its revenue growth expectations for Q1 2024, leading to a stock price drop of $8.35 per share, or 21.3%, closing at $30.89 on February 29, 2024 [4]. - On May 7, 2024, the company cut its full-year 2024 revenue outlook due to reduced ad spending from customers, resulting in a stock price decline of $11.79 per share, or 38.6%, closing at $18.78 on May 8, 2024 [5]. - On February 27, 2025, DoubleVerify reported lower-than-expected Q4 2024 sales and earnings, with a stock price drop of approximately 36%, closing at $13.90 on February 28, 2025 [6]. Industry Concerns - A report by Adalytics Research, LLC on March 28, 2025, claimed that DoubleVerify's advertisement verification services are ineffective, stating that customers are billed for ad impressions served to bots [7]. - The Wall Street Journal reported that DoubleVerify frequently fails to detect nonhuman traffic, contradicting the company's claims of helping brands avoid serving ads to bot accounts [7].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving SelectQuote, Inc. and its officers or directors [1] Group 1: Legal Issues - The U.S. Department of Justice filed a False Claims Act complaint against SelectQuote and other health insurance companies, alleging that from 2016 to 2021, they paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments in Medicare Advantage plans [3] - Following the DOJ's announcement, SelectQuote's stock price dropped by $0.61, or 19.24%, closing at $2.56 per share on May 1, 2025 [3] Group 2: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in fighting for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Iovance Biotherapeutics, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and operational issues [1][2]. Financial Performance - For Q1 2025, Iovance reported a loss of $0.36 per share on revenue of $49 million, missing consensus estimates of a loss of $0.24 per share on revenue of $82 million [2]. - The company's operational bottleneck, caused by a 50% reduction in capacity at the Iovance Cell Therapy Center for a month in December 2024, limited the number of Amtagvi infusions available in Q1 [2]. Stock Market Reaction - Following the announcement of the financial results and operational issues, Iovance's stock price fell by $1.42 per share, or 44.79%, closing at $1.75 per share on May 9, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Redwire Corporation and its executives [1] Financial Performance - Redwire reported Q1 2025 revenue of $61.4 million, missing consensus estimates by $13.14 million, which represents a 30.1% year-over-year decline [2] - The company attributed the revenue decline to delays in U.S. government contract awards due to leadership transitions at agencies like NASA and the Space Development Agency, as well as shifting budget priorities under the Trump administration [2] Stock Market Reaction - Following the financial results announcement, Redwire's stock price fell by $0.75 per share, or 6.63%, closing at $10.56 per share on May 12, 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Fulgent Genetics, Inc. and its officers or directors [1]. Group 1: Investigation Details - The investigation is initiated on behalf of investors of Fulgent Genetics, Inc. [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1]. Group 2: Recent Developments - On February 28, 2025, Fulgent disclosed a civil investigative demand from the U.S. Department of Justice concerning potential false claims under the Uninsured Program [3]. - Following this disclosure, Fulgent's stock price decreased by $0.41 per share, representing a 2.61% decline, closing at $15.28 per share on March 3, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Biohaven Ltd. and its officers or directors [1] Group 1: Company Developments - On May 14, 2025, Biohaven announced that the FDA extended the PDUFA date for its new drug application for the treatment of spinocerebellar ataxia by three months to allow for a full review of recent submissions [3] - Following the FDA announcement, Biohaven's stock price dropped by $3.84 per share, or 19.53%, closing at $15.82 per share on May 15, 2025 [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Biohaven to investigate claims related to potential securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud [4]